Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02607813
Title Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications

Advanced Solid Tumor

Therapies

LXH 254 + Spartalizumab

LXH 254

Age Groups: senior | adult
Covered Countries USA | ITA | FRA | ESP | DEU | CAN

Additional content available in CKB BOOST